| Dominika Maria Dymarczyk, | |
|
2500 Milvia St, Berkeley, CA 94704-2636 | |
| (510) 410-3524 | |
| (510) 506-7722 |
| Full Name | Dominika Maria Dymarczyk |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 4 Years |
| Location | 2500 Milvia St, Berkeley, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437750874 | NPI | - | NPPES |
| 236176 | Other | CA | STATE MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | NM2636176 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sutter Bay Medical Foundation | 4284538778 | 2941 |
News Archive
Sending communications on healthcare benefits through the mail is an important channel in engaging members as they make benefits decisions and as program managers seek to influence member behavior, according to a study on Healthcare Benefit Communications Preferences by Pitney Bowes Management Services, Inc., a wholly owned subsidiary of Pitney Bowes Inc.
Itamar Medical, an international medical technology company developing noninvasive diagnostic technology using the Peripheral Arterial Tone (PAT) Signal, announced today the use of the company's patented Endo-PAT2000 in BioMarin Pharmaceutical Inc.'s phase 2 study of patients with Sickle Cell Disease (SCD). The Endo-PAT2000 was used to measure endothelial function in a study designed to evaluate whether the drug 6R-BH4 can improve endothelial function in SCD patients
A new report from AVAC surveys the state of biomedical HIV prevention research, including the first evidence of vaccine-induced protection in humans and the emergence of ARV-based prevention - and provides strategic recommendations for moving forward in a time of constrained resources and faltering commitment to ending AIDS.
Researchers have found that the blood-thinning drug Lovenox works as well as a standard artery-clearing drug in patients with severe heart-related chest pain, but neither reduced the risk of death after a year of treatment.
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.
› Verified 2 days ago
| Entity Name | Sutter Bay Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013950807 PECOS PAC ID: 4284538778 Enrollment ID: O20031125000909 |
News Archive
Sending communications on healthcare benefits through the mail is an important channel in engaging members as they make benefits decisions and as program managers seek to influence member behavior, according to a study on Healthcare Benefit Communications Preferences by Pitney Bowes Management Services, Inc., a wholly owned subsidiary of Pitney Bowes Inc.
Itamar Medical, an international medical technology company developing noninvasive diagnostic technology using the Peripheral Arterial Tone (PAT) Signal, announced today the use of the company's patented Endo-PAT2000 in BioMarin Pharmaceutical Inc.'s phase 2 study of patients with Sickle Cell Disease (SCD). The Endo-PAT2000 was used to measure endothelial function in a study designed to evaluate whether the drug 6R-BH4 can improve endothelial function in SCD patients
A new report from AVAC surveys the state of biomedical HIV prevention research, including the first evidence of vaccine-induced protection in humans and the emergence of ARV-based prevention - and provides strategic recommendations for moving forward in a time of constrained resources and faltering commitment to ending AIDS.
Researchers have found that the blood-thinning drug Lovenox works as well as a standard artery-clearing drug in patients with severe heart-related chest pain, but neither reduced the risk of death after a year of treatment.
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dominika Maria Dymarczyk, 325 Distel Cir, Los Altos, CA 94022-1408 Ph: (510) 410-3524 | Dominika Maria Dymarczyk, 2500 Milvia St, Berkeley, CA 94704-2636 Ph: (510) 410-3524 |
News Archive
Sending communications on healthcare benefits through the mail is an important channel in engaging members as they make benefits decisions and as program managers seek to influence member behavior, according to a study on Healthcare Benefit Communications Preferences by Pitney Bowes Management Services, Inc., a wholly owned subsidiary of Pitney Bowes Inc.
Itamar Medical, an international medical technology company developing noninvasive diagnostic technology using the Peripheral Arterial Tone (PAT) Signal, announced today the use of the company's patented Endo-PAT2000 in BioMarin Pharmaceutical Inc.'s phase 2 study of patients with Sickle Cell Disease (SCD). The Endo-PAT2000 was used to measure endothelial function in a study designed to evaluate whether the drug 6R-BH4 can improve endothelial function in SCD patients
A new report from AVAC surveys the state of biomedical HIV prevention research, including the first evidence of vaccine-induced protection in humans and the emergence of ARV-based prevention - and provides strategic recommendations for moving forward in a time of constrained resources and faltering commitment to ending AIDS.
Researchers have found that the blood-thinning drug Lovenox works as well as a standard artery-clearing drug in patients with severe heart-related chest pain, but neither reduced the risk of death after a year of treatment.
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.
› Verified 2 days ago
Eva L. Goodfriend-reano, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 2216 Mcgee Ave, Berkeley, CA 94703 Phone: 510-848-1352 Fax: 510-323-2361 | |
Aimee Tom, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 3010 Colby St, Berkeley, CA 94705 Phone: 510-882-2137 | |
Ms. Sallie Peters Hill, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 2450 Ashby Ave, Berkeley, CA 94705 Phone: 510-204-3977 Fax: 510-204-5429 | |
Ms. Lauren L. Galaty, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 2001 Dwight Way, Berkeley Primary Care, Room 1363, Berkeley, CA 94704 Phone: 510-204-4637 | |
Kassandra Marie Donnels, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 2450 Ashby Ave, Berkeley, CA 94705 Phone: 510-204-4444 | |
Kristen Park, Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 2404 Dana St, Apt B, Berkeley, CA 94704 Phone: 408-636-8431 | |
Mrs. Lior Mayer, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 2450 Ashby Ave, Berkeley, CA 94705 Phone: 510-204-3977 Fax: 510-204-5129 |